Literature DB >> 25472674

Improving power to detect changes in blood miRNA expression by accounting for sources of variability in experimental designs.

Sarah I Daniels1, Fenna C M Sillé2, Audrey Goldbaum2, Brenda Yee2, Ellen F Key2, Luoping Zhang2, Martyn T Smith2, Reuben Thomas2.   

Abstract

BACKGROUND: Blood miRNAs are a new promising area of disease research, but variability in miRNA measurements may limit detection of true-positive findings. Here, we measured sources of miRNA variability and determine whether repeated measures can improve power to detect fold-change differences between comparison groups.
METHODS: Blood from healthy volunteers (N = 12) was collected at three time points. The miRNAs were extracted by a method predetermined to give the highest miRNA yield. Nine different miRNAs were quantified using different qPCR assays and analyzed using mixed models to identify sources of variability. A larger number of miRNAs from a publicly available blood miRNA microarray dataset with repeated measures were used for a bootstrapping procedure to investigate effects of repeated measures on power to detect fold changes in miRNA expression for a theoretical case-control study.
RESULTS: Technical variability in qPCR replicates was identified as a significant source of variability (P < 0.05) for all nine miRNAs tested. Variability was larger in the TaqMan qPCR assays (SD = 0.15-0.61) versus the qScript qPCR assays (SD = 0.08-0.14). Inter- and intraindividual and extraction variability also contributed significantly for two miRNAs. The bootstrapping procedure demonstrated that repeated measures (20%-50% of N) increased detection of a 2-fold change for approximately 10% to 45% more miRNAs.
CONCLUSION: Statistical power to detect small fold changes in blood miRNAs can be improved by accounting for sources of variability using repeated measures and choosing appropriate methods to minimize variability in miRNA quantification. IMPACT: This study demonstrates the importance of including repeated measures in experimental designs for blood miRNA research. See all the articles in this CEBP Focus section, "Biomarkers, Biospecimens, and New Technologies in Molecular Epidemiology." ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25472674      PMCID: PMC4256675          DOI: 10.1158/1055-9965.EPI-14-0623

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  30 in total

1.  Faster cyclic loess: normalizing RNA arrays via linear models.

Authors:  Karla V Ballman; Diane E Grill; Ann L Oberg; Terry M Therneau
Journal:  Bioinformatics       Date:  2004-05-27       Impact factor: 6.937

2.  Importance of RNA isolation methods for analysis of exosomal RNA: evaluation of different methods.

Authors:  Maria Eldh; Jan Lötvall; Carina Malmhäll; Karin Ekström
Journal:  Mol Immunol       Date:  2012-04       Impact factor: 4.407

3.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

Review 4.  Gene expression omnibus: microarray data storage, submission, retrieval, and analysis.

Authors:  Tanya Barrett; Ron Edgar
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

5.  Limited dynamic range of immune response gene expression observed in healthy blood donors using RT-PCR.

Authors:  Kevin McLoughlin; Ken Turteltaub; Danute Bankaitis-Davis; Richard Gerren; Lisa Siconolfi; Kathleen Storm; John Cheronis; David Trollinger; Dennis Macejak; Victor Tryon; Michael Bevilacqua
Journal:  Mol Med       Date:  2006 Jul-Aug       Impact factor: 6.354

6.  Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study.

Authors:  Pieter Mestdagh; Nicole Hartmann; Lukas Baeriswyl; Ditte Andreasen; Nathalie Bernard; Caifu Chen; David Cheo; Petula D'Andrade; Mike DeMayo; Lucas Dennis; Stefaan Derveaux; Yun Feng; Stephanie Fulmer-Smentek; Bernhard Gerstmayer; Julia Gouffon; Chris Grimley; Eric Lader; Kathy Y Lee; Shujun Luo; Peter Mouritzen; Aishwarya Narayanan; Sunali Patel; Sabine Peiffer; Silvia Rüberg; Gary Schroth; Dave Schuster; Jonathan M Shaffer; Elliot J Shelton; Scott Silveria; Umberto Ulmanella; Vamsi Veeramachaneni; Frank Staedtler; Thomas Peters; Toumy Guettouche; Linda Wong; Jo Vandesompele
Journal:  Nat Methods       Date:  2014-06-29       Impact factor: 28.547

7.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

8.  Validation of RNA extraction procedures focused on micro RNA expression analysis.

Authors:  M Remáková; M Škoda; M Faustová; J Vencovský; P Novota
Journal:  Folia Biol (Praha)       Date:  2013       Impact factor: 0.906

9.  MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus.

Authors:  Dwi Setyowati Karolina; Arunmozhiarasi Armugam; Subramaniam Tavintharan; Michael T K Wong; Su Chi Lim; Chee Fang Sum; Kandiah Jeyaseelan
Journal:  PLoS One       Date:  2011-08-01       Impact factor: 3.240

10.  Measuring microRNAs: comparisons of microarray and quantitative PCR measurements, and of different total RNA prep methods.

Authors:  Robert A Ach; Hui Wang; Bo Curry
Journal:  BMC Biotechnol       Date:  2008-09-11       Impact factor: 2.563

View more
  6 in total

1.  microRNA Expression in Prospectively Collected Blood as a Potential Biomarker of Breast Cancer Risk in the BCFR.

Authors:  Chin-Wen Chang; Hui-Chen Wu; Mary Beth Terry; Regina M Santella
Journal:  Anticancer Res       Date:  2015-07       Impact factor: 2.480

2.  Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS).

Authors:  Rachel Waller; Emily F Goodall; Marta Milo; Jonathan Cooper-Knock; Marc Da Costa; Esther Hobson; Mbombe Kazoka; Helen Wollff; Paul R Heath; Pamela J Shaw; Janine Kirby
Journal:  Neurobiol Aging       Date:  2017-04-01       Impact factor: 4.673

3.  Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis.

Authors:  Kira Groen; Vicki E Maltby; Rodney A Lea; Katherine A Sanders; J Lynn Fink; Rodney J Scott; Lotti Tajouri; Jeannette Lechner-Scott
Journal:  BMC Med Genomics       Date:  2018-05-21       Impact factor: 3.063

Review 4.  Opportunities Offered by Graphene Nanoparticles for MicroRNAs Delivery for Amyotrophic Lateral Sclerosis Treatment.

Authors:  Benedetta Niccolini; Valentina Palmieri; Marco De Spirito; Massimiliano Papi
Journal:  Materials (Basel)       Date:  2021-12-24       Impact factor: 3.623

5.  SARS-CoV-2 causes a significant stress response mediated by small RNAs in the blood of COVID-19 patients.

Authors:  Xi Liu; Yan-Zi Wen; Zi-Liang Huang; Xia Shen; Jun-Hao Wang; Yi-Hai Luo; Wen-Xin Chen; Zhao-Rong Lun; Hui-Bin Li; Liang-Hu Qu; Hong Shan; Ling-Ling Zheng
Journal:  Mol Ther Nucleic Acids       Date:  2021-12-31       Impact factor: 8.886

6.  A Comprehensive Analysis of MicroRNAs in Human Osteoporosis.

Authors:  Ying Huai; Wenjuan Zhang; Zhihao Chen; Fan Zhao; Wei Wang; Kai Dang; Kaiyue Xue; Yongguang Gao; Shanfeng Jiang; Zhiping Miao; Meng Li; Qiang Hao; Chu Chen; Airong Qian
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-21       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.